By utilizing CA, we revealed that separate clinical features allocated PC patients to the high-risk group of BCR, including GGS ≥ 8, advanced T and N1 status, and PSA ≥ 20 ng/mL, which, consistent with the above, were considered indicators of an aggressive course of PC; in addition, these features corresponded to not only BCR itself but also the presence of the molecular ESR1 and MMP3 signature that was determined to anticipate unfavorable outcomes (Figure 3). Here, BCR is linked to pachyonychia congenita.